Company: OSRH
Filing Date: 2025-06-23
Form Type: 424B3
Source: 0001213900-25-056351
Chunk: 7

Company: OSR Holdings, Inc.
Filing Date: 2025-06-23
Form: 424B3
Chunk 7
---
 that we use in connection with the operation of our business. This prospectus or any documents incorporated
by reference to this prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of
their respective owners. Our use or display of third parties’ trademarks, service marks and trade names or products in this prospectus
or any documents incorporated by reference to this prospectus is not intended to, and does not imply a relationship with, or endorsement
or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus or any documents
incorporated by reference to this prospectus may appear without the ®, TM or SM symbols, but the omission of such references is not
intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the
applicable owner of these trademarks, service marks and trade names.

<div align='center'>ii

PROSPECTUS
SUMMARY</div>

This summary only highlights the more detailed information appearing elsewhere in this prospectus. You should read this entire prospectus carefully, including the information under the section of this prospectus entitled “Risk Factors” and our financial statements and the related notes included elsewhere in this prospectus and/or incorporated by reference herein, before investing.

Company and Business Strategy Overview

We are a global healthcare holding company, with
operations in South Korea and Switzerland and an office in the United States. Our mission is to leverage our existing and expanding
network of academic and industry leaders and investors, including venture capital and private equity, in major healthcare markets globally
to identify, lead and support the growth of our subsidiaries and subsidiary candidates based on innovative research. Subsidiary candidates
are companies that are either already existing entities or new companies formed in connection with acquiring or licensing existing assets
from pharmaceutical firms. We expect to attract industry partners either as co-investors or through technology licensing deals and
may raise capital directly from private, strategic or public investors. We seek to chart a potentially more efficient and optimal route
by pairing what we believe are the right team and pharmaceutical or medical device technologies that have the potential to treat diseases
and improve healthcare outcomes with the necessary financial and other resources. Since our target markets feature large established
global businesses with abundant capital that acquire healthcare companies, we hope to realize additional liquidity through the sale of
our subsidiaries from time to time.

We are a data-driven company.